Protagonist Therapeutics, Inc. (PTGX) News

Protagonist Therapeutics, Inc. (PTGX)

Today's Latest Price: $18.95 USD

0.46 (2.49%)

Updated Oct 30 4:00pm

Add PTGX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter PTGX News Items

PTGX News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest PTGX News From Around the Web

Below are the latest news stories about Protagonist Therapeutics Inc that investors may wish to consider to help them evaluate PTGX as an investment opportunity.

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

Protagonist Therapeutics Reports Granting of Inducement Award

NEWARK, Calif., Sept. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on September 15, 2020, it issued an inducement award to Matthew Gosling, the Company's recently hired Executive Vice President and General Counsel, in accordance with the terms…

PR Newswire | September 15, 2020

The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) Agenus Inc (NASDAQ: AGEN ) Akouos Inc (NASDAQ: AKUS ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC )(reac...

Benzinga | September 11, 2020

Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference

NEWARK, Calif. , Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference. … Full story available on Benzinga.com

Benzinga | September 10, 2020

The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Fluidigm Corporation (NASDAQ: FLDM ) ( announced emergency use authorization for its saliva-based COVID-19 test) Generation Bio Co (NASDAQ: GBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PPD Inc (NASDAQ: PPD ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Silk Road Medical Inc (NASDAQ: SILK ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Polypid Ltd (NASDAQ: PYPD ) Stocks In Focus FDA Approves Companion Diagnos...

Benzinga | August 27, 2020

The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDA...

Benzinga | August 25, 2020

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

Protagonist Therapeutics, Inc. (PTGX): Are Hedge Funds Right About This Stock?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

Yahoo | June 28, 2020

Why Protagonist Should Be On Your Radar After Latest Trial Update

Protagonist Therapeutics (PTGX) is a biotech that should be on your radar after its latest trial update. This involves the release of positive phase 2 data using its drug PTG-300 to treat patients with polycythemia vera. What made the data positive is that all 6 patients that were treated were...

Terry Chrisomalis on Seeking Alpha | June 26, 2020

The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alpine Immune Sciences Inc (NASDAQ: ALPN )( announced a licensing agreement with AbbVie Inc (NYSE: ABBV ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Castle Biosciences Inc (NASDAQ: CSTL ) Cytokinetics, Inc. (NASDAQ: CYTK ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Neubase Therapeutics Inc (NASDAQ: NBSE ) O...

Benzinga | June 19, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5522 seconds.